Polmacoxib

An inhibitor of COX-2 and carbonic anhydrase

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥562.00

450.00

- +
5mg

￥2450.00

1960.00

- +
10mg

￥4262.00

3410.00

- +
25mg

￥8312.00

6650.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci20784
CAS: 301692-76-2
别名: 帕马考昔,CG100649
分子式: C18H16FNO4S
分子量: 361.4
纯度: >98%
溶解度: DMF: 20 mg/ml,DMSO: 20 mg/ml,DMSO:PBS (pH 7.2)(1:8): 0.5 mg/ml,Ethanol: 5 mg/ml
储存: Store at -20°C
库存: 现货

Background

Polmacoxib is an inhibitor of cyclooxygenase 2 (COX-2) and the carbonic anhydrase subtypes I (CAI) and CAII. It inhibits COX-2 in the absence of carbonic anhydrase II with an IC50 value of 40 nM, which increases by approximately 4- and 17-fold in the presence of a CAII at a molar ratio of 1:1 and 1:5, respectively. It also inhibits CAI and CAII (IC50s = 210 and 95 nM, respectively). Polmacoxib prevents >95 and 90% of prostaglandin E2 (PGE2) production in HCA-7 and HT-29 human colon cancer cells, respectively, using concentrations of 0.01 and 0.001 ug/ml. It inhibits polyp formation in a transgenic mouse model of intestinal polyp formation and tumor growth in human colorectal carcinoma mouse xenograft models when used at a dose of 7 mg/kg. The inhibition of COX-2 and CAII by polmacoxib has the potential for fewer serious systemic adverse effects, including cardiovascular events associated with COX-2 selective inhibitors such as celecoxib . Formulations containing polmacoxib have been used in the treatment of osteoarthritis.